SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Eidos
Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage
biopharmaceutical company focused on addressing the large and
growing unmet need in diseases caused by transthyretin (TTR)
amyloidosis (ATTR), today announced the pricing of its initial
public offering of 6,250,000 shares of common stock at a public
offering price of $17.00 per share.
All of the shares are being offered by Eidos. The shares are
expected to begin trading on the Nasdaq Global Select Market on
June 20, 2018 under the ticker symbol
"EIDX." The gross proceeds from the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by Eidos, are expected to be approximately $106.3 million. The offering is expected to close
on June 22, 2018, subject to the
satisfaction of customary closing conditions. In addition, Eidos
has granted the underwriters a 30-day option to purchase up to an
additional 937,500 shares of common stock at the initial public
offering price.
J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as
joint book-running managers for the offering. Barclays Capital Inc.
is also participating as a joint book-running manager.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
June 19, 2018. The offering will be
made only by means of a prospectus, copies of which may be obtained
from J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204,
or by emailing prospectus-eq_fi@jpmchase.com; BofA Merrill Lynch,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by emailing
dg.prospectus_requests@baml.com; or Barclays Capital Inc., c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155
Long Island Avenue, Edgewood, NY
11717, telephone: (888) 603-5847 or by emailing
barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR).
View original
content:http://www.prnewswire.com/news-releases/eidos-therapeutics-announces-pricing-of-initial-public-offering-300669128.html
SOURCE Eidos Therapeutics